By SiriusRx|Education for practices

Clinical review pending. This article has not yet been reviewed by a licensed clinician, and we would rather say so than print a name that does not exist.

A new service line succeeds or fails at the front desk as often as in the exam room. Patients form a first impression from the person who answers the phone, and a well-meaning staff member who says more than they should can create a compliance problem. Training every role, not only the prescribers, is one of the simplest risk controls a practice has.

This article outlines topics for each role. It is general education and names no products. The practice's medical director owns the clinical content.

Front desk and patient coordinators

What they need to know

  • What the service line is, in one or two plain sentences the medical director has approved.
  • What they may say: scheduling, prices the practice has published, and what to expect at a visit.
  • What they must not say: anything about results, safety, or whether a therapy is right for a patient. No comparisons with approved drugs.
  • How to route a clinical question to a clinician, every time.

A script that works: "That is a question for our clinician. I can book a visit so you can talk it through."

Medical assistants and nurses

The practice's own lead decides what this module contains. A complete outline usually covers:

  • Where the practice keeps its reference materials.
  • The tasks each person's license and the practice's delegation agreement already allow, including intake, consent, and follow-up.
  • Storage, labeling, and custody for each pathway the practice uses, including cold storage where the label requires it.
  • How the practice reports a suspected adverse event the same day, and how it runs a recall.

Prescribers

The medical director owns this module. Each prescriber should be able to point to:

  • Which pathway, 503A or 503B, applies to each therapy the practice offers, and where to recheck it.
  • Virginia's in-office rules. Start with in-office administration in Virginia.
  • Where a drug is close to a commercially available one, the prescriber determines, and notes on the prescription, the significant difference it makes for that patient.
  • Consent language that says drugs a pharmacy compounds are not FDA-approved.
  • The limits of any source summary, so a conversation stays inside what the source actually showed.

Practice managers and owners

What they need to know

  • How to vet and revet pharmacy relationships, and how to preserve patient choice of pharmacy.
  • Advertising rules and the substantiation file. See advertising rules for practices.
  • Why the practice accepts no payments, rebates, or free goods from a pharmacy or a manufacturer.
  • Which permits, registrations, and insurance coverages the service line requires.

Keeping training records

  • Record who completed which module and when, with a short check for clinical roles.
  • Train again when materials change, when a therapy is added, and at least once a year.
  • A completion record shows course completion. It is not a license, a credential, or an expansion of anyone's scope of practice. Who may administer injections is set by Virginia law and regulations and the practice's own supervision and delegation arrangements.

A simple launch plan

  1. Week 1: owners and the medical director complete the program overview and the compliance modules.
  2. Week 2: prescribers and nurses complete the pathway and handling modules.
  3. Week 3: the front desk completes scripts and routing, with role-play.
  4. Week 4: run a mock patient journey and a mock recall, then fix what you find.

How SiriusRx helps

The SiriusRx Peptide Program includes role-based training for clinicians and staff, with assessments, completion records, and scripts the team can use on day one. Training is refreshed when the rules change.

General education, not legal or medical advice.

Sources

  • FD&C Act section 503A, 21 U.S.C. 353a: https://www.law.cornell.edu/uscode/text/21/353a.
  • FDA guidance for industry (January 2018) on essentially copies of a commercially available drug product under section 503A: https://www.fda.gov/media/98973/download.
  • FDA, Compounding and the FDA: Questions and Answers: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers.

For practices

Contact us.

This is education for licensed practices. It is not legal, medical, or pharmacy advice, and it does not tell a practice what to prescribe. Contact us with questions about the program.